Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy
- 1 September 2002
- journal article
- Published by Elsevier in The Lancet
- Vol. 360 (9336) , 852-854
- https://doi.org/10.1016/s0140-6736(02)09969-5
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- p53 Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian CarcinomaJournal of Clinical Oncology, 2000
- p53 and cancer therapy: a double-edged swordJournal of Clinical Investigation, 1999
- Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsNature Medicine, 1996
- p53 protein overexpression and chemosensitivity in breast cancerThe Lancet, 1995
- A simple p53 functional assay for screening cell lines, blood, and tumors.Proceedings of the National Academy of Sciences, 1995